SCHEDULE: Farallon Amends Protagonist Therapeutics Stake Disclosure

Farallon Capital Management entities updated their beneficial ownership of Protagonist Therapeutics, Inc. common stock, reflecting internal management changes.

Summary

• Farallon Capital Partners, L.P. and its affiliated entities (the "Farallon Funds") filed an Amendment No. 8 to Schedule 13G regarding their beneficial ownership of Protagonist Therapeutics, Inc. common stock.
• The Farallon Funds collectively hold 6,221,006 shares of common stock and 1,500,000 common stock purchase warrants.
• Due to a beneficial ownership limitation of 9.99%, only 27,007 shares underlying the warrants are currently exercisable within 60 days. The remaining 1,472,993 warrants are not exercisable within this timeframe.
• Several individual managing members and senior managing members of Farallon entities are deemed beneficial owners of 6,248,013 shares, representing 9.99% of the class.
• The filing reflects internal management changes within Farallon Capital Management, L.L.C. and its related general partners.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update reflecting internal changes within a major institutional investor rather than a direct commentary on Protagonist Therapeutics' performance or prospects.

Positives

• Continued significant institutional ownership by Farallon Capital, indicating ongoing investment interest in Protagonist Therapeutics.
• The beneficial ownership limitation of 9.99% suggests a passive investment intent, avoiding the more stringent disclosure requirements of a Schedule 13D.

Risks

• The beneficial ownership limitation on warrants means a substantial portion of potential shares (1,472,993) cannot be immediately converted, limiting Farallon's ability to increase its stake quickly beyond the 9.99% threshold without further regulatory filings or changes in the limitation.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional ownership disclosures like this Schedule 13G are routine for publicly traded companies, providing transparency into significant shareholder positions. Farallon Capital is a prominent hedge fund, and its continued substantial stake in Protagonist Therapeutics suggests a long-term investment thesis, common in the biotechnology sector where development cycles are lengthy.

Management Changes

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake and internal changes affecting beneficial ownership attribution. The continued presence of a large institutional holder like Farallon can be seen as a vote of confidence.
• Management: Awareness of a large, passive institutional holder.

Key Dates

Recommendation

This Schedule 13G Amendment is a routine disclosure of beneficial ownership by a significant institutional investor, Farallon Capital, and primarily reflects internal management changes within Farallon. It does not provide new information regarding Protagonist Therapeutics' operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The continued substantial, albeit passive, stake by Farallon suggests a stable institutional presence, but without further company-specific news, a 'hold' recommendation is appropriate.

Keywords

Protagonist Therapeutics, Farallon Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, SEC Filing, PTGX